Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies.
Verschraegen
C F
CF
Section of Gynecologic Medical Therapeutics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 401, Houston, TX 77030, USA. cverschr@mdanderson.org
Vincent
M
M
Abbruzzese
J L
JL
Siegler
D
D
Kavanagh
J J
JJ
Loyer
E
E
Kudelka
A P
AP
Rubin
E
E
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
C079905:rubitecan; D002945:Cisplatin; D002166:Camptothecin